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Conclusion: This study shows an high consistency of small 
field dosimetry in the involved radiotherapy departments 
using this new generation silicon diode; consequently, the 
values reported may actually be used by other centers as 
indicative values, especially in the case of small fields when 
suitable detector are not commonly available. Moreover, 
these results confirm that the new RAZOR silicon diode can 
be used to assess dosimetric accuracy in small-field delivery. 
In general, the adopted methodology removes much of the 
ambiguity in reporting and interpreting small field dosimetric 
quantities and facilitates a clear dosimetric comparison 
across a population of linacs. 
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Purpose or Objective: Outlining of target and OAR volumes 
is integral to the radiotherapy process but inherently subject 
to variability. The hippocampus is a small structure not 
commonly contoured by clinicians requiring considered 
anatomical interpretation in its delineation. HIPPO is a 
randomised phase II trial of Hippocampal Sparing (HS) versus 
Conventional Whole Brain Radiotherapy after surgical 
resection or radiosurgery in favourable prognosis patients 
with 1-4 brain metastases. We set out to inform the 
development of a dedicated HIPPO RTQA programme through 
evaluation of hippocampal contouring. 
 
Material and Methods: Two clinical oncologists from 
different UK radiotherapy centres and a radiologist from each 
centre independently outlined the hippocampus on 2 
different 1 mm slice thickness planning CT datasets after 
registration with the T1 weighted gadolinium enhanced MRI 
(3D volumetric MRI, axial acquisition, 1 mm slice thickness, 
no slice gap, 1 x 1 x 1 mm voxels) on their planning system. 
The datasets were re-registered by one of the centres. The 
four hippocampal contours for each case were anonymised 
and reviewed collectively and a gold standard contour 
defined. We compared each contour with its respective gold 
standard using the DICE coefficient and volume difference. 
Results: 
 
Table 1 
 
Conclusion: Reasonable concordance of the outlines in 
comparison to the gold standard was achieved in both cases. 
In case 1, all 4 outlines achieved a DICE coefficient greater 
than 0.80 and a hippocampal volume less than 0.5cm3 
different to the gold standard. However, in case 2, despite 
DICE coefficients greater than 0.79 suggesting good spatial 
relationship between the clinicians’ and the gold standard 
contour, greater variability was evident with a larger range in 
volume outlined. During collective review, some systematic 
differences were noted between the two participating 
centres’ outlines, despite a high level of agreement on 
hippocampal boundaries during the review, highlighting CT-
MRI co-registration as a potential source of variability 
between different centres and planning software. As a result 
of these findings, the pre-trial outlining benchmark case 
requires all centres to independently co-register the CT and 
MRI images and export the registration object as part of data 
submission. In order to comprehensively quality assure 
hippocampal outlining as part of the HIPPO RTQA programme, 
an on-trial component of the first two HS patient contours 
being reviewed prospectively before treatment is also 
undertaken. The implementation and quality assurance of 
less familiar outlining practice in the development of 
radiotherapy techniques requires careful consideration. This 
process has informed the development of a dedicated RTQA 
programme for the HIPPO trial highlighting the importance of 
aligning QA with clinical practice. HIPPO is funded by Cancer 
Research UK and The Brain Tumour Charity  
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Purpose or Objective: The ViewRay MRI-Co60 hybrid system 
(MRIdian® [1,2]) is a novel technology that provides soft 
tissue imaging during radiotherapy thus allowing real 
adaptive radiotherapy possibilities and image guidance. The 
combination of Co60 with 0.35 Tesla MRI allows for MR-
guided intensity modulated radiation therapy (IMRT) step and 
shoot delivery with multiple beams (3 Co60 heads 120° 
apart). MRIdian dose calculation takes advantage of a full 
Monte Carlo-based algorithm. The aim of this work was to 
evaluate the repeatability of the dose calculation of MRIdian 
plans for rectal cancer treatments. 
 
Material and Methods: Ten patients affected by locally 
advanced rectal cancer (cT3-cT4; cN0, cN+) were manually 
segmented on Eclipse TPS v11. MRIdian step and shoot IMRT 
plans (7 groups of 3 fields each) were calculated 5 times for 
each patient. The prescribed dose for PTV2 was 45 Gy and 55 
Gy for PTV1 through simultaneous integrated boost. The PTV1 
V95, the conformity index CI [3] and the Wu’s homogeneity 
index HI were computed for each patient. The coefficient of 
variation (CV), defined as the ratio of the standard deviation 
to the mean, was calculated for each set to express the 
precision and repeatability of the Monte Carlo dose 
calculation. The estimated beam-on time was also recorded 
for each plan.  
 
